Mohamed-Eslam F Mohamed
Overview
Explore the profile of Mohamed-Eslam F Mohamed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1068
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Savaryn J, Kikuchi R, Qian Y, Ji Q, Jenkins G, Bow D, et al.
Clin Transl Sci
. 2024 Dec;
17(12):e70109.
PMID: 39688426
Recent reports suggest that plasma riboflavin may serve as a biomarker for BCRP inhibition in humans. However, the clinical data supporting this claim have been limited, with only two studies...
2.
Brunner H, Shmagel A, Horneff G, Foeldvari I, Anton J, Ramanan A, et al.
Arthritis Care Res (Hoboken)
. 2024 Nov;
PMID: 39542836
Objective: This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). Methods: In an...
3.
Qian Y, Schlachter L, Eckert D, Stodtmann S, Shmagel A, Peng Y, et al.
Clin Pharmacol Ther
. 2024 Sep;
116(6):1635-1645.
PMID: 39344158
Juvenile idiopathic arthritis (JIA) is the most prevalent pediatric rheumatic disease. While disease-modifying antirheumatic drugs (DMARDs), especially biologics, have greatly transformed the management of JIA, there remain some unmet medical...
4.
Qian Y, Raymundo E, Hao S, Unnebrink K, Levy G, Teixeira H, et al.
Clin Ther
. 2024 Aug;
46(10):733-741.
PMID: 39142926
Purpose: This study aims to characterize the pharmacokinetics, safety, tolerability, and exploratory efficacy of upadacitinib, an oral Janus kinase inhibitor approved for treating moderate to severe atopic dermatitis (AD) in...
5.
Kikuchi R, Qian Y, Badawi M, Savaryn J, Gannu S, Eldred A, et al.
Clin Pharmacol Ther
. 2024 Aug;
116(5):1334-1342.
PMID: 39102854
Cedirogant is an inverse agonist of retinoic acid-related orphan receptor gamma thymus developed for the treatment of chronic plaque psoriasis. Cedirogant induces cytochrome P450 (CYP) 3A4 while inhibiting P-glycoprotein (P-gp),...
6.
Bhatnagar S, Schlachter L, Eckert D, Stodtmann S, Liu W, Lacerda A, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(5):1240-1251.
PMID: 38982567
Upadacitinib, a selective Janus kinase inhibitor, is the first orally administered therapy approved for the treatment of Crohn's disease (CD). This work characterized the pharmacokinetics of upadacitinib in CD patients...
7.
Merrill J, Tanaka Y, DCruz D, Vila-Rivera K, Siri D, Zeng X, et al.
Arthritis Rheumatol
. 2024 Jun;
76(10):1518-1529.
PMID: 38923871
Objective: The 48-week, phase 2 SLEek study (NCT03978520) evaluated the efficacy and safety of upadacitinib (JAK inhibitor) and elsubrutinib (BTK inhibitor) alone or in combination (ABBV-599) in adults with moderately...
8.
Tyring S, Moore A, Morita A, Hong H, Song I, Eccleston J, et al.
Clin Exp Dermatol
. 2024 May;
49(11):1347-1355.
PMID: 38699939
Background: Dysregulated interleukin (IL)-17/IL-23 signalling contributes to psoriasis pathogenesis. Cedirogant is an inverse agonist of nuclear receptor ROR-gamma isoform 2 (RORyt), a key transcription factor responsible for IL-17 synthesis and...
9.
Mohamed M, Girish S, Humeniuk R, Nuthalapati S, Desai A, Datta-Mannan A, et al.
Clin Pharmacol Ther
. 2024 Mar;
116(1):26-29.
PMID: 38536001
No abstract available.
10.
Mohamed M, Qian Y, DCunha R, Hao S, Carcereri De Prati R, Levy G, et al.
Clin Pharmacol Drug Dev
. 2024 Feb;
13(7):801-809.
PMID: 38410874
Cedirogant is an inverse agonist of retinoic acid-related orphan receptor gamma, thymus (RORγt) developed for treatment of psoriasis. This study aimed to characterize pharmacokinetics, pharmacodynamics, safety, and tolerability of cedirogant...